Mutational landscape and significance across 12 major cancer types
By Cyriac Kandoth, M. McLellan, Fabio Vandin, Kai Ye, Beifang Niu, Charles Lu, Mingchao Xie, Qunyuan Zhang, Joshua F. McMichael, Matthew A. Wyczalkowski and 9 more. Nature, 2013
4,262 citations recorded by the source corpus.
The Cancer Genome Atlas (TCGA) has used the latest sequencing and analysis methods to identify somatic variants across thousands of tumours. Here we present data and analytical results for point mutations and small insertions/deletions from 3,281 tumours across 12 tumour types as part of the TCGA Pan-Cancer effort. We illustrate the distributions of mutation frequencies, types and contexts across tumour types, and establish their links to tissues of origin, environmental/carcinogen influences, and DNA repair defects. Using the integrated data sets, we identified 127 significantly mutated genes from well-known (for example, mitogen-activated protein kinase, phosphatidylinositol-3-OH kinase, Wnt/β-catenin and receptor tyrosine kinase signalling pathways, and cell cycle control) and emerging (for example, histone, histone modification, splicing, metabolism and proteolysis) cellular processes in cancer. The average number of mutations in these significantly mutated genes varies across tumour types; most tumours have two to six, indicating that the number of driver mutations required during oncogenesis is relatively small. Mutations in transcriptional factors/regulators show tissue specificity, whereas histone modifiers are often mutated across several cancer types. Clinical association analysis identifies genes having a significant effect on survival, and investigations of mutations with respect to clonal/subclonal architecture delineate their temporal orders during tumorigenesis. Taken together, these results lay the groundwork for developing new diagnostics and individualizing cancer treatment.
Subfields: Cancer Research, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/6d7fc69b2668ba7e9ed09797615da6e4cee0fcd1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Nicholas McGranahan
- Charles Swanton
- Peter J. Campbell
- Ludmil B. Alexandrov
- David C. Wedge
- Gad Getz
- M. Hollstein
- A. Marusyk
In Molecular Biology
- David Haussler
- Robert M. Kuhn
- Nicholas McGranahan
- Manel Esteller
- Charles Swanton
- W. James Kent
- Mark Diekhans
- Kate R. Rosenbloom
In Pathology and Forensic Medicine
- W. James Kent
- John N. Weinstein
- Peter W. Laird
- David Haussler
- Ingrid A. Mayer
- Peter J. Campbell
- Simone Fulda
Citations in the corpus
- Role of hypoxia in cancer therapy by regulating the tumor microenvironment (2019, background): “Given the central role of mitochondria, the comprehensive connection between HIF, mitochondrial activity, and chemoresistance provides a new direction of research for explaining therapy failure and proposing innovative treatment strategies [116].”
- The UCSC Genome Browser database: 2019 update (2018, background): “We have added a track showing RNA expression data from The Cancer Genome Atlas (TCGA).”
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines (2018, neutral): “Additionally, signifi-cant cancer genes found as part of the original PanCan12 project were highlighted(Kandoth et al., 2013) in this analysis (Figure S4B).”
- Intratumor heterogeneity: the Rosetta stone of therapy resistance (2020, background): “…reactive oxygen species (ROS) induced mutagenesis in a wide range of malignancies, and defects in DNA repair mechanisms, which have been detected in certain tumors (e.g., deficiencies in DNA mismatch repair and APOBEC pathways) (Alexandrov et al., 2013; Fox et al., 2013; Kandoth et al., 2013).”
- A pathology atlas of the human cancer transcriptome (2017, result): “For some patient tumors, the global expression pattern resembles other cancer types more than it does the given type of diagnosed cancer, which reinforces previous discoveries (12).”
- Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors (2018, methodology): “Panel a and b are scaled to the total number of samples with WGS (n=651), WGS or WES (1,639), respectively.”
- Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations (2017, background): “More recently, projects re-sequencing large cohorts of tumors have provided the opportunity to systematically identify genes involved in tumorigenesis through the detection of signals of positive selection in their alteration patterns across tumors of some two dozen malignancies [3 – 6].”